×
About 80,368 results

ALLMedicine™ Hepatitis B Center

Research & Reviews  38,541 results

Biochemical and structural properties of entecavir-resistant hepatitis B virus polymera...
https://doi.org/10.1128/JVI.02401-20
Journal of Virology; Nakajima S, Watashi K et. al.

Jun 2nd, 2021 - Entecavir (ETV) is a widely used anti-hepatitis B virus (HBV) drug. However, the emergence of resistant mutations in HBV reverse transcriptase (RT) results in treatment failure. To understand the mechanism underlying the development of ETV-resista...

Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with h...
https://doi.org/10.1097/MEG.0000000000002217
European Journal of Gastroenterology & Hepatology; Shi K, Li P et. al.

Jun 2nd, 2021 - The neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic marker of hepatocellular carcinoma (HCC); however, the relationship between NLR and risk of HCC occurrence has yet to be systematically elucidated. We aimed to investigate ...

Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
https://doi.org/10.14309/ajg.0000000000001157
The American Journal of Gastroenterology; Nguyen MH, Atsukawa M et. al.

Jun 2nd, 2021 - Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. ETV-treated (≥12 months) chr...

Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatit...
https://doi.org/10.1097/MEG.0000000000002219
European Journal of Gastroenterology & Hepatology; Kosekli MA

Jun 2nd, 2021 - Chronic hepatitis B is associated with important morbidity and mortality. Inflammation has a pivotal role in hepatic fibrosis of this population. Hemogram-derived inflammatory predictors, such as mean platelet volume (MPV) and platelet to lymphocy...

Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine amo...
https://doi.org/10.1080/14760584.2021.1915777
Expert Review of Vaccines; Feng Y, Yao T et. al.

Jun 1st, 2021 - Background: The immunogenicity against hepatitis B vaccine is unsatisfactory in the chronic kidney disease (CKD) patients, and studies evaluating augmented vaccine regimens to enhance immunogenicity have been inconclusive.Objectives: To evaluate t...

see more →

Guidelines  149 results

Screening for Hepatitis B Virus Infection in Adolescents and Adults: Recommendation Sta...
https://www.ncbi.nlm.nih.gov/pubmed/33856166
American Family Physician;

Apr 15th, 2021 - Screening for Hepatitis B Virus Infection in Adolescents and Adults: Recommendation Statement.|2021||blood,diagnosis,prevention & control,blood,diagnosis,prevention & control,

Hepatocellular carcinoma
https://www.nature.com/articles/s41572-020-00240-3
Nature Reviews; Llovet JM

Jan 20th, 2021 - Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepa...

Chemical Risk Factors of Primary Liver Cancer: An Update
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801911/
Hepatic Medicine: Evidence and Research; Barsouk A, Thandra KC et. al.

Jan 4th, 2021 - Primary liver cancer has the sixth highest incidence and fourth highest cancer mortality worldwide. Hepatitis B is the leading cause of liver cancer, though its incidence is decreasing with vaccination. Alcohol is the leading cause of liver transp...

Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Serv...
https://doi.org/10.1001/jama.2020.22980
JAMA , Krist AH et. al.

Dec 15th, 2020 - An estimated 862 000 persons in the US are living with chronic infection with hepatitis B virus (HBV). Persons born in regions with a prevalence of HBV infection of 2% or greater, such as countries in Africa and Asia, the Pacific Islands, and part...

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: A...
https://doi.org/10.1200/JCO.20.01757
Journal of Clinical Oncology : Official Journal of the Am... Hwang JP, Feld JJ et. al.

Jul 27th, 2020 - This Provisional Clinical Opinion update presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management. All patients anticipating systemic anticancer therapy should be tested for HBV by 3 tests-hepatitis B surface an...

see more →

Drugs  253 results see all →

Clinicaltrials.gov  39,879 results

Scottish Study Estimates Risk of Bleeding and Clotting Disorders After AstraZeneca Vaccine
https://www.medscape.com/viewarticle/952747

Jun 8th, 2021 - A nationwide analysis of over 2.5 million Scottish adults who received a first dose of the Oxford/AstraZeneca or Pfizer/BioNTech vaccine between December 2020 and April 2021 has confirmed a small increased risk of immune thrombocytopenic purpura (...

Biochemical and structural properties of entecavir-resistant hepatitis B virus polymera...
https://doi.org/10.1128/JVI.02401-20
Journal of Virology; Nakajima S, Watashi K et. al.

Jun 2nd, 2021 - Entecavir (ETV) is a widely used anti-hepatitis B virus (HBV) drug. However, the emergence of resistant mutations in HBV reverse transcriptase (RT) results in treatment failure. To understand the mechanism underlying the development of ETV-resista...

Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with h...
https://doi.org/10.1097/MEG.0000000000002217
European Journal of Gastroenterology & Hepatology; Shi K, Li P et. al.

Jun 2nd, 2021 - The neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic marker of hepatocellular carcinoma (HCC); however, the relationship between NLR and risk of HCC occurrence has yet to be systematically elucidated. We aimed to investigate ...

Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
https://doi.org/10.14309/ajg.0000000000001157
The American Journal of Gastroenterology; Nguyen MH, Atsukawa M et. al.

Jun 2nd, 2021 - Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. ETV-treated (≥12 months) chr...

Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatit...
https://doi.org/10.1097/MEG.0000000000002219
European Journal of Gastroenterology & Hepatology; Kosekli MA

Jun 2nd, 2021 - Chronic hepatitis B is associated with important morbidity and mortality. Inflammation has a pivotal role in hepatic fibrosis of this population. Hemogram-derived inflammatory predictors, such as mean platelet volume (MPV) and platelet to lymphocy...

see more →

News  1,515 results

Scottish Study Estimates Risk of Bleeding and Clotting Disorders After AstraZeneca Vaccine
https://www.medscape.com/viewarticle/952747

Jun 8th, 2021 - A nationwide analysis of over 2.5 million Scottish adults who received a first dose of the Oxford/AstraZeneca or Pfizer/BioNTech vaccine between December 2020 and April 2021 has confirmed a small increased risk of immune thrombocytopenic purpura (...

Tri-antigenic Vaccine Prevents HBV Infection in Adults
https://www.medscape.com/viewarticle/952116

May 31st, 2021 - NEW YORK (Reuters Health) - A tri-antigenic hepatitis B vaccine (TAV) effectively prevented hepatitis B virus (HBV) infection in adults, was somewhat more effective than a mono-antigenic vaccine (MAV) comparator, but had higher side effect rates i...

SciClone Pharma Tests Hepatitis Drug as COVID-19 Vaccine Enhancer
https://www.medscape.com/viewarticle/949926

Apr 26th, 2021 - BEIJING (Reuters) - China's SciClone Pharmaceuticals has begun a clinical trial to test if its hepatitis B treatment Zadaxin helps to boost immunity provided by COVID-19 vaccines, it said on Monday. SciClone said it is using an inactivated COVID-1...

Treatment Paradigm for Chronic HBV in Flux
https://www.medscape.com/viewarticle/948611

Apr 1st, 2021 - These days deciding when to stop targeted treatment for chronic hepatitis B is a bigger challenge than knowing when to start, Norah A. Terrault, MD, MPH, observed at the Gastroenterology Updates, IBD, Liver Disease Conference. That's because the t...

Progress and Challenges in US Perinatal HBV Prevention Program
https://www.medscape.com/viewarticle/945121

Feb 2nd, 2021 - NEW YORK (Reuters Health) - The United States has made progress in identifying infants born to hepatitis B surface antigen (HBsAg)-positive women and getting them vaccinated. Yet, there is also substantial room for improvement, including closing t...

see more →

Patient Education  31 results see all →